

Eisai builds real-world evidence for blood-based assays for cognitive impairment

24 August 2022 | News

In the diagnosis of people living with cognitive impairment in clinical practice in the US outside of clinical trial settings



Japanese firm Eisai has entered into a Memorandum of Understanding with US-based C2N Diagnostics that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis and appropriate treatment.

Collaborating with C2N, Eisai Inc. will work to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment in clinical practice outside of clinical trial settings in the US.

Blood-based assays could result in the development of new standards in clinical care that may enable timely and accurate diagnoses for people living with cognitive impairment.

The development and adoption of blood-based assays as simple diagnostic tools, in every day clinical practice is an important step in improving care for people in remote and underserved communities where access to the traditional diagnostic tools of positron emission tomography (PET) and lumbar punctures are not a viable option.